If SLA is to really make a go of it as a company and make profits to support future price projections, then it is the medical community that needs to be convinced that BioAlphabets are an effective alternative so they are prescribed. At present SLA are doing few favours to shareholders by being up front about their questionable results. Despite all the disease curing claims made by the Board and posters on discussion boards such as these, SLA's data is woefully short. Knowing that a serious competing drug - simvastatin - is showing more and more promise in treating a whole range of conditions (not only cardiovascular disease, put potentially dementia/Alzheimer’s, Parkinson’s and even MS - with published data to support it), plus is already out on the market and is in the top 30 list of prescribed medications should be a sobering thought for SLA holders who reckon that Ropren is the cure for all medical ills under the sun.
Add to My Watchlist
What is My Watchlist?
